How much AI does your Dr use? Improving approval new drugs?

BTW, you should not use recreational drugs. Only drugs provided by big pharma. This isn't for fun. Capiche?

Future of Health Care

By Caitlin Owens and Adriel Bettelheim, Axios News

Nov 10, 2026

1 big number: AI use by clinicians

Nearly 9 in 10 health providers (89%) report using an AI tool or chatbot for work tasks in the past year, though comparatively few have received any formal training, according to a new West Health-Gallup survey out today.

The big picture: Health professionals are using AI for some of the same reasons as their patients. But as AI use expands, many may need more guidance or other support, particularly when it informs clinical decisions.

What they found: The survey of more than 1,000 primary care physicians found the most common uses in the past year are gathering information about medications (78%) or about symptoms or health conditions (76%).

Over half (53%) used AI to review test results, scans or imaging, while 50% have used it to write clinical notes. Nearly half said they used AI to write patient instructions or after-visit summaries or to record and transcribe patient appointments.

Despite the widespread work-related use, only 20% of providers reported receiving any formal AI training — especially those in physician groups or independent practices.

A separate survey by West Health-Gallup of 5,330 adults found that more than half (56%) who have seen a primary care provider in the past year are comfortable with AI making diagnosis or treatment decisions, as long as the provider can change or override those decisions.

Biotechs urge steps to boost drug discovery

The biotech industry is asking Congress to pass stalled patent legislation and maintain merit-based NIH grant reviews as part of a policy package to help U.S. firms compete with China's biopharma sector.

Why it matters: The seven-point plan comes as economic uncertainty and rising interest rates are slowing the pace of some biopharma deals, and policymakers are scrutinizing certain U.S. investments in China.

Driving the news: The Biotechnology Innovation Organization is urging steps to modernize and streamline U.S. drug development and improve patient access to clinical trials.

The trade group called for the passage of stalled bills that would raise the bar for challenging patents and clarify what kinds of inventions are eligible for patent protection. They would also make it easier for discoveries like gene therapies to be patented.

The group also called on Congress and the administration to sustain support for NIH, FDA and other science agencies and to ensure stable, merit-based grant administration.

The Trump administration has proposed a $5 billion budget cut for NIH in FY27 and adding political reviews to the process for making research grants.

What we're watching: Some of the issues raised could be addressed in next year's reauthorization of FDA user fees.